Who
Robert Baffi
Director
Company insider
Files Form 4 as: Director, Neurogene; Director, Mosaic ImmunoEngineering; President, Global Mfg/Tech Ops, BioMarin Pharmaceutical; Director, Kalobios Pharmaceuticals.
In numbers
- Trades disclosed
- 696
- Buys
- 7
- Sells
- 42
- Bought
- $67K
- Sold
- $41.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 31 Oct 2005
- Last trade
- 20 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,400 at $0.00 | filing |
| 18 Feb 2022filed 22 Feb 2022 | Mosaic ImmunoEngineeringoption or derivative | SEC FORM 4 Code J | — | filing |
| 20 Mar 2020filed 24 Mar 2020 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $256K3,501 at $73.05 | filing |
| 16 Mar 2020filed 17 Mar 2020 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —10,660 at $0.00 | filing |
| 16 Mar 2020filed 17 Mar 2020 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —30,390 at $0.00 | filing |
| 13 Mar 2020filed 17 Mar 2020 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $642K7,600 at $84.50 | filing |
| 3 Mar 2020filed 4 Mar 2020 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —9,852 at $0.00 | filing |
| 5 Jun 2019filed 6 Jun 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —14,160 at $0.00 | filing |
| 30 Apr 2019filed 10 Jun 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | $21K309 at $68.78 | filing |
| 22 Mar 2019filed 26 Mar 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $308K3,501 at $88.05 | filing |
| 15 Mar 2019filed 19 Mar 2019 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —24,120 at $0.00 | filing |
| 15 Mar 2019filed 19 Mar 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $670K7,083 at $94.53 | filing |
| 15 Mar 2019filed 19 Mar 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —9,630 at $0.00 | filing |
| 1 Mar 2019filed 5 Mar 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —11,853 at $0.00 | filing |
| 1 Mar 2019filed 5 Mar 2019 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $87K917 at $94.76 | filing |
| 7 Aug 2018filed 9 Aug 2018 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $543K5,173 at $105.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS GroupBMRN · tickerreport.com · 17 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst SaysBMRN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Robert Baffi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.